Introduction
Compared with placebo, picotamide reduced exerciseinduced microalbuminuria in diabetic subjects with initial nephropathy [12] and halted the progression of Peripheral obstructive arterial disease (POAD) is often complicated by ischaemic episodes occurring not only carotid atherosclerosis in diabetics with macroangiopathy [13 ] . In comparison with aspirin, picotamide in the peripheral circulation but also in coronary and cerebral vessels [1] [2] [3] [4] . The mortality rate for POAD showed a positive effect on microcirculation in diabetic patients with microangiopathy [ 14] . A recent multipatients is 2-3 times higher in comparison with the general population. Diabetes mellitus (DM) is a risk centre study (ADEP trial), carried out in 2304 POAD patients, demonstrated that picotamide reduced vascular factor frequently associated with vascular deterioration and POAD patients with DM have a higher rate of events by 19% on an intention-to-treat basis [ 15] . Here we report a retrospective analysis of the ADEP study amputations and an increased risk for myocardial infarction than non-diabetics [ The ADEP study was a double-blind, randomized, placebo-controlled multicentre trial, stratified by centre, ide might have a particular benefit in DM [12] [13] [14] . carried out in 2304 POAD patients. Full details of the Results study organization and methods have been previously published [15] . After 1-month, single-blind placebo
The characteristics of the patients in the two groups were similar at the time of randomization with mean run-in period, eligible patients, after obtaining their informed consent, were given either picotamide (300 mg durations of diabetes of 5.8 and 5.3 years in the picotamide and placebo group respectively; 7% and 5% three times daily) or placebo and followed for 18 months. The present paper shows the results of a of the patients in the picotamide and placebo group respectively were using insulin. Oral antidiabetic treatretrospective analysis carried out in a subgroup of 438 diabetic patients. ment was used by 20% and 21% of picotamide and placebo patients respectively. Hypercholesterolaemia was present in 36% of picotamide treated patients and in 29% of placebo group. Hypertriglyceridaemia was Patients observed in 33% and 34% of the picotamide and placebo group respectively; 15% on picotamide and POAD was defined as leg pain on walking that 16% on placebo had a clinical history of coronary heart disappeared after 5 min at rest, and an ankle/arm disease, whereas 13% on picotamide and 8% on placebo pressure index by Doppler ultrasonography ≤0.85 or had previous cerebrovascular disease. Comparable perclaudication with previous amputation/reconstructive centages of patients (21% on picotamide and 25% on vascular surgery. Exclusion criteria were: treatments placebo) had previously undergone surgery or angioplawith antiplatelet, non-steroidal anti-inflammatory and sty for cardiovascular disease. Concomitant treatments anticoagulant drugs; pain at rest, skin lesions and were equally distributed in the two groups. During the myocardial infarction or stroke in the previous 3 study, 27 patients were lost to follow-up, 16 (7%) on months. Patients were examined every 3 months and all picotamide and 11 (5%) on placebo. Side effects occurred vascular event documentations were sent to an indepenin 15% of patients on picotamide and 17% of patients dent review committee for event validation which was on placebo. No difference between the two groups was conducted blind to treatment allocation.
observed in the frequency of gastrointestinal complaints (10% both in picotamide and placebo). The intentionto-treat analysis for major and other events in diabetic patients is shown in Table 1 . Vascular events occurred Outcomes in 18 (8%) patients of picotamide group and in 32 (15%) in those of placebo group (relative risk reduction: The events taken into consideration during the ADEP 48%; 95% CI: 26, 76; P=0.02; log-rank test). Patients study were the following: vascular and non-vascular taking picotamide had six major events (3%) and 12 death, fatal and non-fatal myocardial infarction (MI), other events (6%), whereas patients taking placebo had fatal and non-fatal stroke, amputation above the ankle 12 major (6%) and 20 minor events (10%) (relative risk for reasons other than tumours or trauma and excision reduction for major events: 56%; 95% CI:21, 143 ). of ischaemic viscera. MI and stroke were considered Event-free survival curves are shown in Figure 1 . fatal if death occurred within 1 month of the qualifying event. These events were defined as major events. Other vascular events included: recently developed angina or unstable angina, possible or probable MI, transient Discussion ischaemic attacks (TIA), minor stroke (defined as a focal ischaemic cerebrovascular event resulting in minimal
The results of this retrospective analysis of the ADEP permanent neurologic deficit and at least 80% recovery study indicated that, in POAD patients with DM, of function within 3 weeks), and deterioration of vascular picotamide reduced the relative risk of vascular events disease leading to surgical intervention, angioplasty or by 48%. This effect was greater than that observed in local thrombolysis. If a patient had both a major and the general POAD population, in which picotamide other vascular event, only the major was counted; each reduced the risk of vascular events by 19%. These patient contributed only one event.
findings are in agreement with other clinical studies which demonstrated a positive effect of picotamide in diabetic patients [12] [13] [14] . Taken together, the results of these trials in diabetic patients suggest a potential use Statistical analysis of picotamide in preventing vascular disease in this clinical condition. The main limitation of the present Event-free analysis was performed on the subset of diabetic patients, establishing survival curves according study is that it involves a post-hoc analysis of the diabetic subgroup patients enrolled in the large scale to the Kaplan-Meier method. The patients lost to follow-up and those who withdrew alive were considered ADEP trial; therefore these results should be interpreted with caution. Our findings are based on a secondary as censored in the intention-to-treat analysis. The null hypothesis H 0 : h=1, where h is the odds ratio of the analysis of the principal study and the potential efficacy of picotamide needs to be further evaluated in a two curves, was tested by the log-rank test. 95% confidence intervals were also calculated. The Proc prospective trial planned to analyze its effect in claudicant patients with diabetes mellitus. Therefore our Lifetest was used (SAS 6.04) to perform this analysis. 
